Zosano Pharma Corporation (ZSANQ) stock profile

Frequently asked questions

What does Zosano Pharma Corporation (ZSANQ) do?

Zosano Pharma Corporation operates as a clinical-stage biopharmaceutical firm dedicated to supplying medicines and other biologically active compounds to patients experiencing migraine episodes. Its innovative transdermal microneedle system serves as the vehicle for this delivery. The company's flagship product, Qtrypta (M207), is a unique formulation of zolmitriptan intended for the immediate management of acute migraines. Zosano Pharma was founded in 2006 and maintains its headquarters in Fremont, California. Notably, on June 1, 2022, the company sought voluntary reorganization protection by filing for Chapter 11 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware.

Where is ZSANQ stock listed?

Zosano Pharma Corporation trades under the ticker ZSANQ on OTC.

How can I research ZSANQ's financials and filings?

Vantafin provides Zosano Pharma Corporation's income statement, balance sheet and cash-flow data, SEC filings, earnings-call transcripts, and insider & institutional ownership on the ZSANQ profile.